BRTX-100 Cell Therapy for Chronic Lumbar Disc Disease

BRTX-100 Cell Therapy for Chronic Lumbar Disc Disease
81%55%30%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 26 • YES 38.0%Apr 27 • YES 49.0%Apr 28 • YES 53.5%Apr 29 • YES 49.0%Apr 30 • YES 49.0%May 1 • YES 49.0%May 2 • YES 49.4%May 3 • YES 49.4%May 4 • YES 49.8%May 5 • YES 67.9%May 6 • YES 38.0%May 7 • YES 72.4%May 13 • YES 69.9%
BioRestorative Therapies ($BRTX)
No stock closeNo stock close$0.30$0.22$0.14Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 27 • BRTX $0.23Apr 28 • BRTX $0.22Apr 29 • BRTX $0.20Apr 30 • BRTX $0.23May 1 • BRTX $0.23May 4 • BRTX $0.24May 5 • BRTX $0.25May 6 • BRTX $0.24May 7 • BRTX $0.23May 8 • BRTX $0.21May 11 • BRTX $0.20May 12 • BRTX $0.20May 13 • BRTX $0.19

Will this trial show a positive result on Primary Efficacy Endpoint: Clinical response, defined as at least a 30% decrease in pain as measured on the VAS scale and at least a 30% increase in function based on the ODI at Week 52 as compared to baseline?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
No oracle findings have been stored for this trial yet.
Stats
Latest Run
No runs yet
Model
No runs yet
Runs
0 runs